This research study is evaluating the safety and efficacy of a combination drug and biologic
therapy in patients with advanced head and neck cancer.
This research study involves the following drugs and biologics:
- CIML NK donor cells
- IL-15 superagonist
- Ipilimumab
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Altor BioScience Bristol-Myers Squibb Miltenyi Biomedicine GmbH Miltenyi Biotec B.V. & Co. KG